English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Most carbapenem-nonsusceptible  Enterobacterales  (CNSE) produce carbapenemases, but some isolates do not carry these enzymes. Ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MBV), and imipenem-relebactam (IMR) have activity against CNSE isolates producing serine-carbapenemases, but these agents might have variable activity against isolates that do not produce these enzymes. We evaluated the activity of these agents against a collection of 170 carbapenemase-negative CNSE collected during 5 years in US hospitals.    Methods    Enterobacterales  isolates (n=47,858) collected in US hospitals from 2016-2020 were susceptibility (S) tested by reference broth microdilution methods. Results were interpreted using CLSI 2020 breakpoints. CNSE displayed nonsusceptible (NS) MICs for imipenem or meropenem. CNSE isolates were screened for carbapenemase genes using whole genome sequencing.    Results  Among 685 (1.4% of the isolates) CNSE, 170 (24.8% of the CNSE) isolates did not produce carbapenemases. Most of these isolates were  K. aerogenes  (n=42),  K. pneumoniae  (32), and  E. cloacae  (32), but 13 other species also were carbapenemase negative. CAZ-AVI inhibited all carbapenemase-negative CNSE isolates (Figure). MBV and IMR inhibited 97.6% and 92.3% of the isolates. Amikacin (AMK) and tigecycline (TIG) inhibited 97.1% and 93.5%, while levofloxacin and meropenem (MEM) inhibited 63.5% and 64.7%. A total of 141 (82.9%) isolates were nonsusceptible (NS) to imipenem. When MEM NS isolates (n=60) were analysed separately, the S rates were lower for all agents except CAZ-AVI. CAZ-AVI inhibited all MEM NS carbapenemase-negative CNSE isolates. MBV and IMR inhibited 93.1% and 89.7% of these isolates, respectively. AMK and TIG inhibited 93.3% and 88.3%, respectively. Only 8.3% of the isolates were resistant to colistin.    Conclusion  CAZ-AVI displayed good activity against carbapenemase-negative CNSE isolates, including all MEM NS that displayed greater resistance rates against all comparator agents. High-risk patients with infections caused by CNSE have an increased mortality rate compared to isolates susceptible to these agents. Implementation of appropriate therapy for these isolates is critical.Disclosures    Mariana Castanheira, PhD ,  AbbVie (formerly Allergan ) (Research Grant or Support) Bravos Biosciences  (Research Grant or Support) Cidara Therapeutics, Inc.  (Research Grant or Support) Cipla Therapeutics  (Research Grant or Support) Cipla USA Inc.  (Research Grant or Support) GlaxoSmithKline  (Research Grant or Support) Melinta Therapeutics, Inc.  (Research Grant or Support) Melinta Therapeutics, LLC  (Research Grant or Support) Pfizer, Inc.  (Research Grant or Support) Qpex Biopharma  (Research Grant or Support) Shionogi  (Research Grant or Support) Spero Therapeutics  (Research Grant or Support)  Mariana Castanheira, PhD , Affinity Biosensors (Individual(s) Involved: Self): Research Grant or Support; Allergan (Individual(s) Involved: Self): Research Grant or Support; Amicrobe, Inc (Individual(s) Involved: Self): Research Grant or Support; Amplyx Pharma (Individual(s) Involved: Self): Research Grant or Support; Artugen Therapeutics USA, Inc. (Individual(s) Involved: Self): Research Grant or Support; Astellas (Individual(s) Involved: Self): Research Grant or Support; Basilea (Individual(s) Involved: Self): Research Grant or Support; Beth Israel Deaconess Medical Center (Individual(s) Involved: Self): Research Grant or Support; BIDMC (Individual(s) Involved: Self): Research Grant or Support; bioMerieux Inc. (Individual(s) Involved: Self): Research Grant or Support; BioVersys Ag (Individual(s) Involved: Self): Research Grant or Support; Bugworks (Individual(s) Involved: Self): Research Grant or Support; Cidara (Individual(s) Involved: Self): Research Grant or Support; Cipla (Individual(s) Involved: Self): Research Grant or Support; Contrafect (Individual(s) Involved: Self): Research Grant or Support; Cormedix (Individual(s) Involved: Self): Research Grant or Support; Crestone, Inc. (Individual(s) Involved: Self): Research Grant or Support; Curza (Individual(s) Involved: Self): Research Grant or Support; CXC7 (Individual(s) Involved: Self): Research Grant or Support; Entasis (Individual(s) Involved: Self): Research Grant or Support; Fedora Pharmaceutical (Individual(s) Involved: Self): Research Grant or Support; Fimbrion Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Fox Chase (Individual(s) Involved: Self): Research Grant or Support; GlaxoSmithKline (Individual(s) Involved: Self): Research Grant or Support; Guardian Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Hardy Diagnostics (Individual(s) Involved: Self): Research Grant or Support; IHMA (Individual(s) Involved: Self): Research Grant or Support; Janssen Research & Development (Individual(s) Involved: Self): Research Grant or Support; Johnson & Johnson (Individual(s) Involved: Self): Research Grant or Support; Kaleido Biosceinces (Individual(s) Involved: Self): Research Grant or Support; KBP Biosciences (Individual(s) Involved: Self): Research Grant or Support; Luminex (Individual(s) Involved: Self): Research Grant or Support; Matrivax (Individual(s) Involved: Self): Research Grant or Support; Mayo Clinic (Individual(s) Involved: Self): Research Grant or Support; Medpace (Individual(s) Involved: Self): Research Grant or Support; Meiji Seika Pharma Co., Ltd. (Individual(s) Involved: Self): Research Grant or Support; Melinta (Individual(s) Involved: Self): Research Grant or Support; Menarini (Individual(s) Involved: Self): Research Grant or Support; Merck (Individual(s) Involved: Self): Research Grant or Support; Meridian Bioscience Inc. (Individual(s) Involved: Self): Research Grant or Support; Micromyx (Individual(s) Involved: Self): Research Grant or Support; MicuRx (Individual(s) Involved: Self): Research Grant or Support; N8 Medical (Individual(s) Involved: Self): Research Grant or Support; Nabriva (Individual(s) Involved: Self): Research Grant or Support; National Institutes of Health (Individual(s) Involved: Self): Research Grant or Support; National University of Singapore (Individual(s) Involved: Self): Research Grant or Support; North Bristol NHS Trust (Individual(s) Involved: Self): Research Grant or Support; Novome Biotechnologies (Individual(s) Involved: Self): Research Grant or Support; Paratek (Individual(s) Involved: Self): Research Grant or Support; Pfizer (Individual(s) Involved: Self): Research Grant or Support; Prokaryotics Inc. (Individual(s) Involved: Self): Research Grant or Support; QPEX Biopharma (Individual(s) Involved: Self): Research Grant or Support; Rhode Island Hospital (Individual(s) Involved: Self): Research Grant or Support; RIHML (Individual(s) Involved: Self): Research Grant or Support; Roche (Individual(s) Involved: Self): Research Grant or Support; Roivant (Individual(s) Involved: Self): Research Grant or Support; Salvat (Individual(s) Involved: Self): Research Grant or Support; Scynexis (Individual(s) Involved: Self): Research Grant or Support; SeLux Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Shionogi (Individual(s) Involved: Self): Research Grant or Support; Specific Diagnostics (Individual(s) Involved: Self): Research Grant or Support; Spero (Individual(s) Involved: Self): Research Grant or Support; SuperTrans Medical LT (Individual(s) Involved: Self): Research Grant or Support; T2 Biosystems (Individual(s) Involved: Self): Research Grant or Support; The University of Queensland (Individual(s) Involved: Self): Research Grant or Support; Thermo Fisher Scientific (Individual(s) Involved: Self): Research Grant or Support; Tufts Medical Center (Individual(s) Involved: Self): Research Grant or Support; Universite de Sherbrooke (Individual(s) Involved: Self): Research Grant or Support; University of Iowa (Individual(s) Involved: Self): Research Grant or Support; University of Iowa Hospitals and Clinics (Individual(s) Involved: Self): Research Grant or Support; University of Wisconsin (Individual(s) Involved: Self): Research Grant or Support; UNT System College of Pharmacy (Individual(s) Involved: Self): Research Grant or Support; URMC (Individual(s) Involved: Self): Research Grant or Support; UT Southwestern (Individual(s) Involved: Self): Research Grant or Support; VenatoRx (Individual(s) Involved: Self): Research Grant or Support; Viosera Therapeutics (Individual(s) Involved: Self): Research Grant or Support; Wayne State University (Individual(s) Involved: Self): Research Grant or Support  Rodrigo E. Mendes, PhD ,  AbbVie  (Research Grant or Support) AbbVie (formerly Allergan ) (Research Grant or Support) Cipla Therapeutics  (Research Grant or Support) Cipla USA Inc.  (Research Grant or Support) ContraFect Corporation  (Research Grant or Support) GlaxoSmithKline, LLC  (Research Grant or Support) Melinta Therapeutics, Inc.  (Research Grant or Support) Melinta Therapeutics, LLC  (Research Grant or Support) Nabriva Therapeutics  (Research Grant or Support) Pfizer, Inc.  (Research Grant or Support) Shionogi  (Research Grant or Support) Spero Therapeutics  (Research Grant or Support)  Helio S. Sader, MD, PhD, FIDSA ,  AbbVie (formerly Allergan ) (Research Grant or Support) Basilea Pharmaceutica International, Ltd.  (Research Grant or Support) Cipla Therapeutics  (Research Grant or Support) Cipla USA Inc.  (Research Grant or Support) Department of Health and Human Services  (Research Grant or Support, Contract no. HHSO100201600002C) Melinta Therapeutics, LLC  (Research Grant or Support) Nabriva Therapeutics  (Research Grant or Support) Pfizer, Inc.  (Research Grant or Support) Shionogi  (Research Grant or Support) Spero Therapeutics  (Research Grant or Support)

open forum infectious diseases

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible <i>Enterobacterales</i> that Are Carbapenemase-Negative

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative